What is Milestone Pharmaceuticals?
Milestone Pharmaceuticals is a specialized biopharmaceutical entity dedicated to the advancement of innovative cardiovascular medicines. The company focuses primarily on the development of novel therapies for heart rhythm disorders, aiming to bridge the gap between unmet patient needs and effective clinical solutions. By leveraging deep scientific expertise and strategic collaborations across North America, Milestone operates at the intersection of medical research and commercial application. Its market position is defined by a robust portfolio of therapeutic candidates designed to improve patient outcomes and provide scalable treatment options for chronic cardiovascular conditions.
How much funding has Milestone Pharmaceuticals raised?
Milestone Pharmaceuticals has raised a total of $412.5M across 8 funding rounds:
Series A
$13M
Series B
$17M
Series C
$55M
Series D
$80M
Stock Offering
$94.9M
Share Placement
$25M
Other Financing Round
$125M
Series A (2011): $13M led by Business Development Bank of Canada, GO Capital, Fonds de Solidarité FTQ, Pappas Ventures, iNovia Healthcare Ventures, and Fonds Bio-Innovation
Series B (2015): $17M supported by Fonds de solidarité FTQ, GO Capital, Pappas Ventures, Inovia, Domain Associates, and BDC Capital
Series C (2017): $55M featuring Tekla Capital Management, Fonds de solidarité FTQ, GO Capital, Pappas Capital, BDC Capital, Novo Holdings, Domain Associates, and Forbion
Series D (2018): $80M backed by Domain Associates, RTW Investments, Tekla Capital Management, Fonds de solidarité FTQ, GO Capital, Venrock Healthcare Capital Partners, Novo Holdings, BDC Capital, Boxer Capital, Forbion, and Pappas Capital
Stock Issuance/Offering (2019): $94.9M, investors not publicly disclosed
Share Placement (2020): $25M led by RTW Investments , LP
Other Financing Round (2023): $125M supported by RTW Investments
Key Investors in Milestone Pharmaceuticals
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a track record of supporting numerous IPOs and M&A events.
Pappas Capital
Pappas Capital is a leading healthcare venture capital firm that specializes in advancing biopharma, biotech, and medical technologies aimed at improving patient outcomes.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
What's next for Milestone Pharmaceuticals?
With the recent strategic investment, Milestone Pharmaceuticals is well-positioned to accelerate its clinical trial programs and expand its research capabilities. The company's strategic roadmap likely involves advancing its lead therapeutic candidates through late-stage clinical development while strengthening its operational infrastructure. By maintaining a focus on high-impact cardiovascular innovation, the firm is poised to enhance its competitive standing in the global biopharma market. Future growth will likely be driven by the successful execution of its clinical milestones and the potential commercialization of its proprietary pipeline, supported by the continued backing of its seasoned investor syndicate.
See full Milestone Pharmaceuticals company page
